Jacque Sokolov's healthcare-only family office and a $50 million biotech loss

Jacque Sokolov has run a family office in a single industry for three decades, and The Family Office Professional's profile of him supplies both halves of that record: the healthcare bets, and a $50 million loss on seven biotech companies that the profile says came in a single swing. Sokolov is described as candid about why patience separates the wins from the losses, which puts the loss inside the argument rather than at the edge of it.

He is chairman and CEO of SSB, a holding company that doubles as his family office and holds four units—SSB Solutions, SSB Investment Funds, SSB Financial Services and SSB Governmental Services—so the investment arm sits beside businesses that sell into healthcare systems, health plans and government payers, leaving the office's exposure to its chosen sector to run through service revenue as well as through equity. That arrangement also puts the investment arm inside a company run by the same person who runs everything else, which means thesis and capital meet at one desk, though the account does not say how capital moves among the four units or whether the operating arms are funded from the investment side.

If the service units work with the same health plans and government payers that the investment arm underwrites, the office would be collecting market intelligence in the ordinary course of business rather than only in diligence. The coverage presents the four units as a list and describes no such flow between them, so the connection is an inference from the names rather than a stated practice.

"Our journey in investing in healthcare has been an evolutionary one that has focused on major inflection points in transformative technology over the past 30 years," Sokolov says, and returns, on that account, came from recognizing those inflection points rather than from holding a broad slice of the sector. That places the office nearer a specialist operator than a diversified allocator that happens to own healthcare, and waiting for inflection points also implies fewer and larger commitments than a spread across the industry would produce. The account names no specific inflection point the office invested behind, which leaves the method described at the level of principle rather than example.

The profile withholds the data an allocator would want first—fund-level performance, assets under management for SSB Investment Funds, a current list of holdings—and offers two hard figures instead: the $50 million loss and a $100 million savings number from Sokolov's earlier career on the purchasing side of healthcare.

Before he was an investor, he was a buyer of care, spending five years as CEO of the health plan at Southern California Edison, described in the profile as the second-largest self-funded, self-administered corporate healthcare system in the U.S. at the time, covering more than 60,000 employees, retirees and dependents and controlling both the financing and the delivery of their healthcare. Running both the financing and the delivery meant owning the coverage decision, which is the decision that determines whether a drug, device or service gets paid for at all.

His account of those years is a cost-control story with numbers attached. "Over a five-year period, Edison was one of the most successful corporate healthcare systems," he says. "We saved in excess of $100 million, or about 15% below what we otherwise would have spent on healthcare. And we launched some of the very creative benefit structures that would be widely adopted by other companies."

That last claim is the one a healthcare allocator should weigh most carefully, because a buyer who designs benefit structures other employers then copy has been early to changes in how care gets paid for, which is the same judgment required to assess whether a portfolio company's product will be reimbursed. The discipline he carried out of the plan was, in his words, "the validation of the quality, access, and cost equation of all healthcare delivery," a standard set on the purchasing side of the market and later applied on the owning side.

He left Edison and used the formula he had refined there to build Advanced Health Plans, Inc., the first major business under the SSB banner, then sold it to Coastal Healthcare in 1994, at the start of the physician practice management boom, becoming chairman of the board and a large shareholder. Converting an operating company into a stake in the acquirer keeps exposure to the sector while changing its nature from payroll and contracts to a security, though the account records the move without describing the terms, so what the Coastal stake was worth or how it was later resolved is not part of it. Equity appreciation from that business and from other holdings let him found SSB Investments about three years later, which places the investment arm's founding in the late 1990s, with the sector knowledge kept in-house rather than handed to outside managers.

The passage most likely to be useful to another healthcare allocator is Sokolov's account of what has changed in getting advances paid for. "We have wonderful clinical advances still going on," he says. "But the time to get those clinical advances out to the marketplace continues to be protracted, because the legal and regulatory requirements, the business payment challenges, and the provider adoption methodologies are now much more arduous than they were 10 or 20 years ago."

That is a statement about duration. Duration is the variable a family office with no redemption calendar is best placed to carry. If regulation, payment and provider adoption add years between a clinical result and a revenue line, the equity holder is financing a longer runway than the science alone implies, and the underwriting question shifts from whether a technology works to whether a payment pathway will exist by the time it does, which favors investors who can read the payer's side and not only the clinic's.

It also explains why this kind of capital suits the sector: a closed-end fund has to return money on a schedule set before the regulatory clock was known, while a family office does not, and that absence of a redemption date is what allows a position to sit through a delayed approval. Patience cannot manufacture a payment pathway, which is why the $50 million across seven biotech companies reads less like a failure of selection than a demonstration of how wide the distribution gets when the rules, rather than the science, set the schedule. The account does not say whether those seven positions were held in one vintage or spread across the three decades; the loss is presented as a single episode.

Without the size of the office's capital base, which the coverage does not give, the loss cannot be expressed as a share of it, and while seven companies and $50 million works out to about $7 million apiece if the positions were equal, that condition is not established, and a loss of that scale would change how a committee approaches the next biotech commitment.

What the profile does establish is the shape of the office's risk budget. A single-sector family office is a different instrument from a diversified one: its advantage is knowledge built over a career that began on the buyer's side of the table, and its exposure is that the knowledge covers one industry at a moment when, by Sokolov's own account, that industry's timetable keeps stretching. Concentration buys an information edge that a diversified portfolio cannot purchase, and it means a bad vintage lands in full on one balance sheet; how large that acceptance should be is a question each office's committee answers for itself, and the coverage does not address how SSB sets it.

The $100 million saved at Edison belongs to a benefits budget rather than a fund, measured against what the company would otherwise have spent, while the $50 million belongs to the family office's own capital. Both came out of the same habit of keeping score against the quality, access and cost equation Sokolov says he has applied throughout, and the next decade of the record will settle whether that scorecard still fits a sector where the gap between an advance and a payment for it has grown longer.